Twist, Centogene to develop rare disease assay kits

By The Science Advisory Board staff writers

October 7, 2021 -- Twist Bioscience and Centogene have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases.

The kits will be designed to make genetic testing more accessible to patients and add to the understanding of rare diseases. Their collaboration aims to augment the bio databank on rare diseases and may contribute to the discovery and development of new therapies to treat these diseases in the future, the companies said.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.